Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs
AssigneeNovartis AG
InventorsDavid Jenkins, Ming Lei, Andreas Loew, Li Zhou
Life of this patent
Estimating the term…
Abstract
The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.
Claims30
A method of treating a disease mediated by a canonical Wnt signaling pathway comprising the step of administering to a subject in need thereof an effective amount of a composition comprising a low density lipoprotein-related protein 6(LRP6) construct, wherein said construct comprises
- (a) first and second LRP6 single chain Fv molecules (scFvs) or fragments thereof that bind to LRP6;
- and
- (b) a human serum albumin;
- wherein the first and second scFv molecules or fragments thereof are linked to the N- and C-termini of the human serum albumin, wherein the LRP6 construct inhibits a canonical Wnt signal transduction pathway, and wherein the the LRP6 construct displays no significant potentiation of a Wnt signal in the presence of an LRP6 binding protein, and wherein the disease is a cancer.
Dependencies are inferred from the claim text.